Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
NCT00100243
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Plenaxis
Sponsor
PRAECIS Pharmaceuticals Inc.